TheraRadar
Data updated: May 26, 2026

NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE (nicardipine hydrochloride)

Cardiovascular Approved 2024-04-17

Nicardipine hydrochloride helps patients with chronic stable angina, specifically chest pain triggered by physical exertion. It also treats high blood pressure and can be used on its own or in combination with other heart and blood pressure medications. When used for hypertension, clinicians should monitor the drug's effect closely due to the notable variation in blood pressure control between peak and trough levels.

Source: FDA Label • INFORLIFE

How NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE Works

This medication works by blocking the movement of calcium ions into cardiac and vascular smooth muscle cells through specific channels. By inhibiting this influx, the drug helps relax coronary vascular smooth muscle while having a greater effect on blood vessels than on the heart muscle itself. This process occurs without altering the concentration of calcium in the blood.

Source: FDA Label
1
Indication
--
Phase 3 Trials
2
Years on Market

Details

Status
Prescription
First Approved
2024-04-17
Routes
INTRAVENOUS
Dosage Forms
INJECTABLE

Companies

Active Ingredient: NICARDIPINE HYDROCHLORIDE

NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE Approval History

2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2024 to 2024
Apr 2024 ORIGINAL
Update

What NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE Treats

2 indications

NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE is approved for 2 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Angina
  • Hypertension
Source: FDA Label

NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 12 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMLODIPINE BESYLATE AND VALSARTAN
AMLODIPINE BESYLATE
2 shared
Viatris
Shared indications:
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE
AMLODIPINE BESYLATE
2 shared
Teva
Shared indications:
CADUET
AMLODIPINE BESYLATE
2 shared
PHARMACIA
Shared indications:
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT03098680 PRIME PRIME (A094136) Ph 1 terminated A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems
NCT01810302 results posted 034-2013 Ph 2 terminated Safety Study of Nicardipine to Treat Cerebral Vasospasm
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE FDA Label Details

Indications & Usage

NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE is indicated for the treatment of Angina; Hypertension.

Track NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.